CASE REPORT| Volume 47, ISSUE 3, P251-255, October 2003

Download started.


The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports


      We present two cases of tuberculous meningitis (TBM) in adults complicated by focal neurological deficits which showed progression whilst on steroids. In case 1 an MRI demonstrated multiple ring-enhancing lesions compressing the optic chiasm leading to a bitemporal hemianopia. After the introduction of thalidomide serial imaging and field perimetry at 6, 9, 12 and 24 months into treatment showed progressive improvement. In case 2, two months into anti-tuberculous treatment with steroids, the patient developed fluctuating right sided paralysis with the MRI demonstrating a large ring-enhancing mass encasing the left internal carotid and middle cerebral arteries. Thalidomide was introduced as an immunomodulatory adjunct and subsequently the patient made a complete neurological recovery. The immunomodulatory effects of thalidomide may have a role in the acute and chronic management of TBM complicated by intracranial tuberculomas.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Medical Research Council
        Streptomycin in tuberculosis trials committee. Streptomycin treatment of tuberculous meningitis.
        Lancet. 1948; 1: 582-597
        • Horne N.W.
        A critical evaluation of corticosteroids in tuberculosis.
        Bibl Tuberc. 1966; 22: 1-54
        • Prasad K.
        • Volmink J.
        • Menon G.R.
        Steroids for treating tuberculous meningitis.
        Cochrane Database Syst Rev. 2000; 3 (CD002244)
        • Afghani B.
        • Lieberman J.M.
        Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review.
        Clin Infect Dis. 1994; 19: 1092-1099
        • Miyoshi Y.
        • Noda S.
        • Murai H.
        • Itoh H.
        Repeated deterioration of tuberculous meningitis due to a reduction in the corticosteroid dosage during chemotherapy.
        Rinsho Shinkeigaku. 2000; 40: 1018-1022
      1. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408–414.

        • Tsenova L.
        • Bergtold A.
        • Freedman V.H.
        • Young R.A.
        • Kaplan G.
        Tumour necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system.
        Proc Natl Acad Sci USA. 1999; 96: 5657-5662
        • Tavares J.L.
        • Wangoo A.
        • Dilworth P.
        • Marshall B.
        • Kotecha S.
        • Shaw R.J.
        Thalidomide reduces tumour necrosis factor alpha production by human alveolar macrophages.
        Resp Med. 1997; 91: 31-39
        • Moreira A.L.
        • Tsenova-Berkova L.
        • Wang J.
        • et al.
        Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis.
        Tuber Lung Dis. 1997; 78: 47-55
        • Tsenova L.
        • Sokol K.
        • Freedman V.H.
        • Kaplan G.
        A combination of thalidomide plus antibiotics protects rabbits from Mycobacterial meningitis-associated death.
        J Infect Dis. 1998; 177: 1563-1572
        • Schoeman J.F.
        • Springer P.
        • Ravenscroft A.
        • et al.
        Adjuctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role.
        J Child Neurol. 2000; 15: 497-503
        • Schoeman J.F.
        Thalidomide therapy in childhood meningitis.
        J Child Neurol. 2000; 15: 838
        • Gori A.
        • Rossi M.C.
        • Marchetti G.
        • et al.
        Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculous disease.
        AIDS. 2000; 14: 1859-1861
        • Haslett P.A.
        • Corral L.G.
        • Albert M.
        • Kaplan G.
        Thalidomide costimulates primary human T lymphocytes preferentially inducing proliferation, cytokine production and cytokine responses in the CD8+ subset.
        J Exp Med. 1998; 187: 1885-1892
        • Marriott J.B.
        • Clarke I.A.
        • Dredge K.
        • Muller G.
        • Stirling D.
        • Dalgleish A.G.
        Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
        Clin Exp Immunol. 2002; 130: 75-84
        • Tsenova L.
        • Mangaliso B.
        • Muller G.
        • et al.
        Use of ImiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.
        Antimicrob Agents Chemother. 2002; 46: 1887-1895